RGNX - Rasio kapitalisasi pasar marang pendapatan REGENXBIO Inc
REGENXBIO Inc. (RGNX) is minimally susceptible to market volatility, as its success depends on patents and clinical trials. The historical P/S ratio illustrates the valuation trend, where the value 3.30 expresses the state of the metric. Growth is driven by NAV-vector licenses that generate royalties. Supply reliability is guaranteed by liquid nitrogen transportation, which is critical for preserving the properties of biomaterials.
regenxbio.com (RGNX) - rincian metrik lan laporan keuangan
- kuotasi saiki lan rata-rata prakiraan nilai:
- statistik kapitalisasi pasar:
- indikator kapitalisasi buku:
- statistik kawajiban utang lan likuiditas:
Rasio Total Utang marang Ekuitas REGENXBIO Inc.|RGNX - Rasio utang jangka dawa marang ekuitas|Koefisien utang jangka cendhak marang modal regenxbio.com|RGNX - Utang perusahaan|Rasio utang marang aset resik REGENXBIO Corp|RGNX - Utang jangka dawa perusahaan|Tanggungan jangka cendhak REGENXBIO|Rasio likuiditas darurat regenxbio.com
- data bathi resik lan rasio valuasi:
RGNX - Penghasilan resik|Prakiraan bathi resik REGENXBIO Inc.|RGNX - Pangali P/E|Rasio rega marang bathi mangsa ngarep REGENXBIO Corp|RGNX - Rasio rega marang bathi tumrap wutah|Nilai perusahaan marang bathi operasional sadurunge panyusutan REGENXBIO Corp|RGNX - Bathi operasional EBITDA|Bathi resik saben saham (EPS TTM) REGENXBIO|RGNX - Bathi saben saham sajrone rolas wulan pungkasan|Wutah bathi saben siji saham taun-ka-taun sajrone 12 wulan pungkasan regenxbio.com|RGNX - Wutah bathi ing taun lumaku|Prakiraan wutah bathi resik saben saham ing taun ngarep REGENXBIO Inc.
- data total pendapatan lan volume dodolan:
Analisis fundamental perusahaan:REGENXBIO, RGNX
Investors assess the resilience of REGENXBIO Inc. (RGNX) through the price-to-sales ratio, which is critical for a business generating stable royalties from the licensing of the Inertia platform. By analyzing the company's P/S ratio, you determine the extent of the premium paid for future cash flows from patents, where extreme values on the chart signal either inflated market expectations or stagnating operational efficiency.
Perusahaan pesaing
TEM (Tempus AI, Inc.) - Rasio kapitalisasi pasar marang pendapatan|Qiagen Group - Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan IONS|RGEN - Rasio rega marang pendapatan|Koefisien rega marang pendapatan Avidity Biosciences RNA|CRSP: Multiplikator P/S|Rasio kapitalisasi marang pendapatan WGS|RARE (Ultragenyx Pharma) - Multiplikator P/S|Multiplikator P/S Beam Therapeutics Inc.|Rasio rega marang pendapatan Sarepta Therapeutics Inc (SRPT)|Twist Bioscience - Rasio kapitalisasi marang pendapatan|10x Genomics Inc - Kapitalisasi marang pendapatan|NTLA (Intellia Therapeutics, Inc.) - Rasio rega marang dodolan|Stoke Corp - Multiplikator P/S|BLFS (BioLife) - Rasio kapitalisasi marang pendapatan|wavelifesciences.com (WVE) - Rasio rega marang pendapatan|MAZE - Koefisien rega marang pendapatan|SION (Sionna Therapeutics, Inc.) - Multiplikator P/S|Kapitalisasi marang pendapatan Prime Medicine Corp (PRME)|Multiplikator P/S TSHA|Multiplikator P/S uniQure N.V. (QURE)|Rasio rega marang pendapatan MeiraGTx Holdings plc MGTX|SLDB: Rasio kapitalisasi marang pendapatan|OCGN: Kapitalisasi marang pendapatan|PACB - Multiplikator P/S|BNTC (Benitec Corp) - Kapitalisasi marang pendapatan|Multiplikator rega marang pendapatan Design Corp DSGN|Rasio rega marang pendapatan Rocket Pharmaceuticals|Multiplikator P/S 4D Molecular Therapeutics, Inc.|Rasio rega marang pendapatan Lexeo (LXEO)|KRRO (Korro Bio Inc.) - Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S EDIT (Editas Medicine, Inc.)|Multiplikator P/S Silence Therapeutics Corp SLN|PRQR - Rasio rega marang pendapatan|Koefisien rega marang pendapatan Codexis Inc CDXS|SGMO: Multiplikator P/S|Rasio kapitalisasi marang pendapatan NAUT|Rasio rega marang pendapatan metagenomi.co|Multiplikator P/S Precision BioSciences Inc.|Multiplikator P/S GBIO|Boundless Bio, Inc. - Rasio kapitalisasi marang pendapatan|Multiplikator P/S XCUR (Exicure, Inc.)|Koefisien rega marang pendapatan Imunon, Inc. (IMNN)|PHIO - Rasio rega marang pendapatan|Rasio kapitalisasi pasar marang pendapatan MBIO (mustangbio.com)|RNAZ: Multiplikator P/S|Rasio kapitalisasi marang pendapatan BNGO|APDN (Applied DNA Corp) - Multiplikator P/S|BLUE: Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan ImmunoPrecise (IPA)|OMGA - Rega marang dodolan|Rasio rega marang pendapatan Singular Genomics OMIC|Rasio kapitalisasi pasar marang pendapatan RGLS|Syros Pharmaceuticals, Inc. - Multiplikator P/S|Koefisien rega marang pendapatan Telesis Bio Inc. TBIO|TRACON Pharmaceuticals, Inc. (TCON) - Rasio rega marang pendapatan|Unity Biotechnology, Inc - Rasio kapitalisasi pasar marang pendapatan
